(Reuters) - Mylan NV said it would launch the first generic version of its allergy auto-injector EpiPen for $300 (229 pounds), half the price of the branded product, the drugmaker's second step in ...
(Reuters) - Mylan NV said it would launch the first generic version of its allergy auto-injector EpiPen for $300, half the price of the branded product, the drugmaker's second step in less than a week ...
WASHINGTON (Reuters) -The U.S. Supreme Court on Monday declined to hear a bid by Sanofi SA to revive its antitrust lawsuit accusing rival pharmaceutical company Viatris Inc of illegally monopolizing ...